Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sumgen Completes $32 Million Round for Immunotherapy Antibodies

publication date: Oct 1, 2020

Sumgen Biotech of Hangzhou completed a $32 million Series B funding round to advance its portfolio of novel immunotherapy antibodies. The round was led by Addor Capital and co-led by Cowin Capital and Sinowisdom Investment. The proceeds will be used to fund clinical trials of the company's pipeline of ten oncology mAbs and construction of an antibody production facility in Hangzhou. Also participating in the round were BOCOM International, Shanghai Haoshuo Investment and Dynamic Capital. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021